dapagliflozin
astrazeneca
['heart failure']
these data provide further evidence to support the use of an sglt2 inhibitor as foundational therapy in patients with heart failure, regardless of care setting or ejection fraction. #deliver #esccongress 
Cardiology Pharmacist. Cwm Taf Morgannwg University Health Board. (All views are my own)